Bausch Health Companies (NYSE:BHC) Given New $32.00 Price Target at Morgan Stanley
Posted by ABMN Staff on Feb 11th, 2020 // No Comments
Bausch Health Companies logoBausch Health Companies (NYSE:BHC) had its target price dropped by investment analysts at Morgan Stanley from $34.00 to $32.00 in a research report issued to clients and investors on Tuesday, BenzingaRatingsTable reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s target price would suggest a potential upside of 14.78% from the stock’s current price.
A number of other research firms have also recently issued reports on BHC. Barclays restated a “buy” rating and issued a $33.00 price objective on shares of Bausch Health Companies in a research report on Sunday, January 26th. Piper Jaffray Companies boosted their price target on shares of Bausch Health Companies from $30.00 to $39.00 and gave the company an “overweight” rating in a research report on Monday, December 30th. Zacks Investment Research cut shares of Bausch Health Companies from a “buy” rating to a “hold” rating and set a $33.00 price target on the stock. in a research report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Bausch Health Companies in a research report on Monday, December 23rd. Finally, TheStreet upgraded shares of Bausch Health Companies from a “d+” rating to a “c” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $34.06.
BHC stock opened at $27.88 on Tuesday. The firm’s 50-day moving average price is $28.97 and its two-hundred day moving average price is $25.42. Bausch Health Companies has a 12-month low of $18.72 and a 12-month high of $31.97. The stock has a market capitalization of $9.92 billion, a price-to-earnings ratio of -15.84, a PEG ratio of 0.58 and a beta of 1.02. The company has a current ratio of 1.15, a quick ratio of 0.86 and a debt-to-equity ratio of 9.17.
A number of institutional investors and hedge funds have recently made changes to their positions in BHC. Carolina Wealth Advisors LLC bought a new position in Bausch Health Companies during the fourth quarter valued at approximately $31,000. Bessemer Group Inc. raised its position in Bausch Health Companies by 5,071.8% in the fourth quarter. Bessemer Group Inc. now owns 2,017 shares of the company’s stock worth $60,000 after acquiring an additional 1,978 shares during the period. Aigen Investment Management LP bought a new position in Bausch Health Companies in the fourth quarter worth approximately $95,000. Fieldpoint Private Securities LLC bought a new position in Bausch Health Companies in the fourth quarter worth approximately $104,000. Finally, IFP Advisors Inc raised its position in Bausch Health Companies by 2,293.9% in the fourth quarter. IFP Advisors Inc now owns 3,543 shares of the company’s stock worth $105,000 after acquiring an additional 3,395 shares during the period. Institutional investors and hedge funds own 57.38% of the company’s stock.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Recommended Story: Most Active Stocks
Analyst Recommendations for Bausch Health Companies (NYSE:BHC)
News 
Market Data 
Discover 
